Related Experiment Video

Updated: May 19, 2026

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Factors that influence parental attitudes toward enrollment in type 1 diabetes trials

Daniela L Buscariollo1, Mario A Davidson, Margo Black

  • 1Department of Pediatrics, Ian Burr Division of Endocrinology and Diabetes, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.

Plos One
|September 1, 2012
PubMed

Insights

Parental willingness to enroll children in type 1 diabetes clinical trials (T1DCTs) is moderate but influenced by trial design. Effective communication addressing concerns like placebo use is key to increasing participation.

Area of Science:

  • Pediatric Endocrinology
  • Clinical Trial Recruitment
  • Patient Engagement

Background:

  • Type 1 diabetes clinical trials (T1DCTs) are crucial for advancing treatment.
  • Understanding parental attitudes is essential for successful trial recruitment.

Purpose of the Study:

  • To evaluate parental attitudes toward T1DCTs.
  • To identify factors influencing enrollment willingness for children with and without diabetes.

Main Methods:

  • A cross-sectional survey was conducted among parents of children with type 1 diabetes.
  • Data collected at an academic clinic and a diabetes educational event.

Main Results:

  • 76% of parents were aware of T1DCTs; 47% were willing to enroll children with diabetes versus 36% without.
  • Only 18% recalled being asked to enroll, and less than 30% were comfortable with placebo use.
  • Healthcare provider trust and comfort with proxy consent significantly predicted willingness.

Conclusions:

  • Parental willingness for T1DCT enrollment is moderate but impacted by trial methodologies.
  • Improved communication addressing parental concerns (e.g., placebo, "guinea pig" fears) may enhance participation.
  • Low recall of being asked to participate suggests a communication gap.
Abstract

More Related Videos

Electrochemiluminescence Assays for Human Islet Autoantibodies09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

Related Concept Videos

Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...